Cargando…

No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis

OBJECTIVE: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcus, Julia L., Glidden, David V., Mayer, Kenneth H., Liu, Albert Y., Buchbinder, Susan P., Amico, K. Rivet, McMahan, Vanessa, Kallas, Esper Georges, Montoya-Herrera, Orlando, Pilotto, Jose, Grant, Robert M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867330/ https://www.ncbi.nlm.nih.gov/pubmed/24367497 http://dx.doi.org/10.1371/journal.pone.0081997

Ejemplares similares

HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial
por: Liegler, Teri, et al.
Publicado: (2014)

HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial
por: Deutsch, Madeline B., et al.
Publicado: (2015)

Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial
por: Solomon, Marc M., et al.
Publicado: (2014)

Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial
por: Kuebler, Peter J., et al.
Publicado: (2016)

A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis
por: Fuchs, Jonathan D., et al.
Publicado: (2018)

Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men
por: Marcus, Julia L., et al.
Publicado: (2014)

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
por: Amico, K. Rivet, et al.
Publicado: (2014)

Statistical issues in trials of preexposure prophylaxis
por: Dunn, David T., et al.
Publicado: (2016)

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)
por: Defechereux, Patricia A., et al.
Publicado: (2015)

Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network
por: Spinelli, Matthew A, et al.
Publicado: (2019)

The European preexposure prophylaxis revolution
por: Cairns, Gus, et al.
Publicado: (2016)

Eligibility for HIV Preexposure Prophylaxis, Intention to Use Preexposure Prophylaxis, and Informal Use of Preexposure Prophylaxis Among Men Who Have Sex With Men in Amsterdam, the Netherlands
por: Hulstein, Sebastiaan H., et al.
Publicado: (2021)

Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study
por: Amico, K. Rivet, et al.
Publicado: (2016)

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users
por: Smith, Dawn K., et al.
Publicado: (2013)

In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?
por: Mitchell, Kate M., et al.
Publicado: (2018)

Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors
por: Janes, Holly, et al.
Publicado: (2019)

The use of preexposure treatments for HIV prophylaxis
por: Majid, Adrian, et al.
Publicado: (2012)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
por: Solomon, Marc M., et al.
Publicado: (2014)

Optimizing Provider Preexposure Prophylaxis (PrEP) Training: A Cross-Sectional Analysis of Recommendations from Providers Across the PrEP Implementation Cascade
por: Rao, Sharanya, et al.
Publicado: (2021)

The Ethical Relevance of “Alternatives” in Health Care Priority Setting – The Case of Preexposure Prophylaxis (PrEP) of HIV
por: Gustavsson, Erik, et al.
Publicado: (2022)

Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study
por: Liu, Albert Y, et al.
Publicado: (2019)

Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women
por: Anderson, Peter L., et al.
Publicado: (2016)

Oral preexposure prophylaxis continuation, measurement and reporting
por: Stankevitz, Kayla, et al.
Publicado: (2020)

From trials to the public health: pre-exposure prophylaxis for HIV prevention
por: Kallas, Esper Georges, et al.
Publicado: (2013)

Technology-Based Interventions to Promote the HIV Preexposure Prophylaxis (PrEP) Care Continuum: Protocol for a Systematic Review
por: Hong, Chenglin, et al.
Publicado: (2022)

HPV vaccination and HIV preexposure prophylaxis (PrEP): Missed opportunities for anal cancer prevention among at risk populations
por: Wheldon, Christopher W.
Publicado: (2022)

P41 - Preexposure prophylaxis of infants’ food allergy
por: Denisova, Svetlana, et al.
Publicado: (2014)

Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care
por: Krakower, Douglas, et al.
Publicado: (2019)

Effect of 6-Month HIV Preexposure Prophylaxis Dispensing With Interim Self-testing on Preexposure Prophylaxis Continuation at 12 Months: A Randomized Noninferiority Trial
por: Ortblad, Katrina F., et al.
Publicado: (2023)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
por: Fonner, Virginia A., et al.
Publicado: (2016)

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
por: Donnell, Deborah, et al.
Publicado: (2017)

Preexposure Prophylaxis for the Prevention of HIV Infection — 2014 Available Online
Publicado: (2014)

Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States
por: Aaron, Erika, et al.
Publicado: (2018)

HIV Preexposure Prophylaxis in the U.S. Military Services — 2014–2016
por: Blaylock, Jason M., et al.
Publicado: (2018)

Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19
por: Kulkarni, Chanda, et al.
Publicado: (2021)

Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada
por: Knox, David C., et al.
Publicado: (2022)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

Developing and Assessing the Feasibility of a Home-based Preexposure Prophylaxis Monitoring and Support Program
por: Siegler, Aaron J, et al.
Publicado: (2019)

Awareness of and Preferences for Preexposure Prophylaxis (PrEP) among MSM at High Risk of HIV Infection in Southern China: Findings from the T2T Study
por: Chen, Weiying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hrc7mqbch2d63nrprmedrt9k2p